scholarly journals Improved Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) Associated with Bone Marrow as the Stem Cell Source in Adults

2016 ◽  
Vol 22 (3) ◽  
pp. S49
Author(s):  
Rohtesh S. Mehta ◽  
Regis Peffault deLatour ◽  
Todd E. Defor ◽  
Marie Robin ◽  
Aleksandr Lazaryan ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
Stem Cell Source ◽  
Cell Source ◽  
Disease Free

scholarly journals Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults

Haematologica ◽  
2016 ◽  
Vol 101 (6) ◽  
pp. 764-772 ◽  
Author(s):  
R. S. Mehta ◽  
R. P. de Latour ◽  
T. E. DeFor ◽  
M. Robin ◽  
A. Lazaryan ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
Stem Cell Source ◽  
Cell Source ◽  
Disease Free

scholarly journals Current Graft-versus-Host Disease–Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant

2017 ◽  
Vol 23 (7) ◽  
pp. 1208-1214 ◽  
Author(s):  
Scott R. Solomon ◽  
Connie Sizemore ◽  
Xu Zhang ◽  
Michelle Ridgeway ◽  
Melhem Solh ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
Disease Free

No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors

Blood ◽  
2001 ◽  
Vol 98 (6) ◽  
pp. 1739-1745 ◽  
Author(s):  
Mats Remberger ◽  
Oolle Ringdén ◽  
Igor-Wolfgang Blau ◽  
Hellmut Ottinger ◽  
Bernhard Kremens ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Chronic Gvhd ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Free Survival ◽  
Graft Versus Host ◽  
Unrelated Donors ◽  
Disease Free

Abstract The clinical results in 107 patients receiving a peripheral blood stem cell (PBSC) graft mobilized by granulocyte colony-stimulating factor (G-CSF) from HLA-A, -B, and -DR–compatible unrelated donors were compared to 107 matched controls receiving unrelated bone marrow (BM) transplants. Engraftment was achieved in 94% of the patients in both groups. The PBSC graft contained significantly more nucleated cells, CD34+, CD3+, and CD56+ cells (P < .001), and resulted in a significantly shorter time-to-neutrophil (15 versus 19 days) and platelet engraftment (20 versus 27 days), compared to the BM control group (P < .001). Probabilities of acute graft-versus-host disease (GVHD) grades II to IV were 35% and 32% (not significant [NS]) and of chronic GVHD 61% and 76% (NS) in the PBSC and BM groups, respectively. There was no difference between the 2 groups in bacteremia, cytomegalovirus reactivation or disease, and fungal infection. The 3-year transplant-related mortality (TRM) rates were 42% in the PBSC group and 31% in the BM controls (P = .7) and the survival rates were 46% and 51%, respectively. The probability of relapse was 25% and 31% in both groups (NS), resulting in disease-free survival rates of 43% in the PBSC group and 46% in the BM controls (NS). In the multivariate analysis, early disease, acute GVHD grade 0 to I, and presence of chronic GVHD were independent factors associated with a better disease-free survival in this study. PBSC from HLA-compatible unrelated donors can be used safely as an alternative to BM for stem cell transplantation.

scholarly journals Validation of the Composite End Point of Graft-Versus-Host Disease-Free, Relapse-Free Survival

2016 ◽  
Vol 22 (3) ◽  
pp. S339-S340
Author(s):  
Kenji Motohashi ◽  
Masatsugu Tanaka ◽  
Jun Taguchi ◽  
Maki Hagihara ◽  
Kenji Matsumoto ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
End Point ◽  
Disease Free
Sign in / Sign up

Export Citation Format

Share Document